CTXR - キティウス・ファ―マシュ―ティカルズ （Citius Pharmaceuticals Inc.） キティウス・ファ―マシュ―ティカルズCTXRのチャート
CTXRの企業情報
| symbol | CTXR |
|---|---|
| 会社名 | Citius Pharmaceuticals Inc （キティウス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Citius Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products adjunctive cancer care and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30 2016 the Company had not generate any revenues. キティウス・ファ―マシュ―ティカルズは米国の特殊医薬品メ―カ―。抗感染症薬、がん補助療法、処方薬に焦点を置いた治療薬の開発や商品化に従事する。開発中の薬剤には、カテ―テル関連血流感染を対象とした抗菌薬ロックソリュ―ション「Mino-Lok」や、痔核治療での炎症や麻酔痛を軽減するヒドロコルチゾン-リドカイン局所製剤がある。本社所在地はニュ―ジャ―ジ―州。 Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. |
| 本社所在地 | 11 Commerce Drive First Floor Cranford NJ 07016 USA |
| 代表者氏名 | Leonard L. Mazur Leonard L. Mazur |
| 代表者役職名 | Executive Chairman of the Board Secretary |
| 電話番号 | +1 908-967-6677 |
| 設立年月日 | 40422 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 7人 |
| url | www.citiuspharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ctxr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.52810 |
| 終値（lastsale） | 1.7899 |
| 時価総額（marketcap） | 28994216.0109 |
| 時価総額 | 時価総額（百万ドル） 27.69993 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 25.11109 |
| 当期純利益 | 当期純利益（百万ドル） -12.73298 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Citius Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $9.7M. Higher net loss reflects Research and Development increase of 96% to $4.8M (expense) General and administrative increase of 8% to $4.7M (expense) Gain/Loss on Derivatives - Hedging decrease from $309K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.48 to -$1.01. |
CTXRのテクニカル分析
CTXRのニュース
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering 2023/05/08 17:42:00 Kwhen Finance
Citius Pharmaceuticals Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date | MarketScreener 2023/04/25 13:42:24 MarketScreener
CRANFORD - Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it… | April 25, 2023
Why Aaron''s Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket 2023/04/25 12:03:04 Benzinga
Gainers ZeroFox Holdings, Inc. (NASDAQ: ZFOX ) gained 36.7% to $1.49 in pre-market trading after dropping around 17% on Monday. ZeroFox completed the acquisition of LookingGlass Cyber Solutions, Inc. Virios Therapeutics, Inc. (NASDAQ: VIRI ) shares climbed 32.3% to $0.8291 in pre-market trading after the company reported initial FDA feedback on proposed IMC-1 Phase 3 program for the treatment of fibromyalgia. Mangoceuticals, Inc. (NASDAQ: MGRX ) gained 21% to $2.36 in pre-market trading after jumping around 32% on Monday. SeqLL Inc. (NASDAQ: SQL ) surged 17.3% to $0.5399 in pre-market trading after gaining 5% on Monday. Agrify Corporation (NASDAQ: AGFY ) gained 14.6% to $0.2438 in pre-market trading. Agrify announced termination of warrant inducement transaction. Grom Social Enterprises, Inc. (NASDAQ: GROM ) climbed 13.4% to $0.68 in pre-market trading after dropping around 4% on Monday. cbdMD, Inc. (NYSE: YCBD ) climbed 13.1% to $5.73 in pre-market trading. cbdMD, recently reported a 1-for-45 reverse stock split of its common stock.
Citius Pharmaceuticals Moving Forward With Spin Out Efforts For New Public Company For I/ONTAK 2023/04/03 12:02:41 Benzinga
Maxim Group to serve as financial advisor in the spin out of Citius Pharmaceutical’s oncology asset, I/ONTAK, into a standalone publicly-traded company. The FDA is reviewing the biologics license application (BLA) for I/ONTAK''s, with a targeted action date set for July 28, 2023. Citius aims to maximize I/ONTAK''s value and advance its pipeline, subject to all customary approvals. Late-stage biopharmaceutical company Citius Pharmaceuticals has announced that Maxim Group will serve as … Full story available on Benzinga.com
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids 2023/04/03 12:00:00 PR Newswire
Topline Results anticipated by the end of Q2 2023 CRANFORD, N.J., April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company''s Phase 2b clinical study of Halo-Lido (CITI-002),…
Citius Pharmaceuticals GAAP EPS of -$0.23 beats by $0.01 2022/12/22 21:33:38 Seeking Alpha
Citius Pharmaceuticals press release (CTXR): FY GAAP EPS of -$0.23 beats by $0.01.As of September 30, 2022, the Company had $41.7 million in cash and cash equivalents. The…
Have you been able to find a good deal on Citius Pharmaceuticals Inc.’s shares? 2022/12/02 14:16:00 US Post News
In Thursday’s session, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) marked $1.23 per share, up from $1.17 in the previous session. While Citius Pharmaceuticals Inc. has overperformed by 5.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CTXR fell by -23.12%, with highs and lows ranging from $2.01 to […]
Citius stock rises as I/ONTAK gets FDA review for rare blood cancer 2022/12/01 14:19:33 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) accepted for review Citius Pharmaceuticals'' (CTXR) application seeking approval of denileukin diftitox (I/ONTAK or E7777) to treat…
Citius Pharmaceuticals secures $3.6M through NJEDA 2022/11/21 13:46:26 Seeking Alpha
Citius Pharmaceuticals (CTXR) to participate in more commonly known as the Net Operating Loss Program, and will receive $3.6M in non-dilutive capital through the New Jersey…
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Stock: Looks Like A Good Investment 2022/11/19 16:30:00 Stocks Register
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) shares, rose in value on Friday, 11/18/22, with the stock price up by 1.83% to the previous day’s close as strong demand from buyers drove the stock to $1.11. Actively observing the price movement in the last trading, the stock closed the session at $1.09, falling within a range of $1.06 … Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Stock: Looks Like A Good Investment Read More »
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 2022/10/06 20:30:00 PR Newswire
CRANFORD, N.J., Oct. 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will be…
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings 2022/09/23 10:48:57 Benzinga
Citius Pharmaceuticals Inc (NASDAQ: CTXR ) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. (NYSE: MRK ) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. The investigator-initiated trial at UPMC is an open-label, Phase 1/1b study consisting of two parts. Part I is a dose escalation study of four cohorts and … Full story available on Benzinga.com
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/07 12:30:00 PR Newswire
Chairman & CEO of Citius, Leonard Mazur, to present September 14, 2022 at 11:00am ET CRANFORD, N.J., Sept. 7, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C. Wainwright 24th Annual…
Can Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Still Be Considered A Loss When It’s Down -20.78% YTD? 2022/08/27 19:00:00 Marketing Sentinel
During the last session, Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s traded shares were 0.34 million, with the beta value of the company hitting 1.51. At the end of the trading day, the stock’s price was $1.22, reflecting an intraday loss of -4.69% or -$0.06. The 52-week high for the CTXR share is $2.35, that puts it down … Can Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Still Be Considered A Loss When It’s Down -20.78% YTD? Read More »
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Stock Gained 34.67% Over A Month – Any Room To Run? 2022/08/20 11:00:00 Marketing Sentinel
Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s traded shares stood at 0.67 million during the last session, with the company’s beta value hitting 1.48. At the close of trading, the stock’s price was $1.18, to imply a decrease of 0.00% or $0.0 in intraday trading. The CTXR share’s 52-week high remains $2.35, putting it -99.15% down since that … Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Stock Gained 34.67% Over A Month – Any Room To Run? Read More »